
|Videos|July 2, 2013
Episode 14 - Concerns about Rising Costs of Treatment
Advertisement
Episodes in this series

During this segment, the panelists discuss their concerns about the rising costs of drugs currently available to treat multiple sclerosis (MS).
Gary M. Owens, MD, states that it is unclear why drug prices continue to rise, especially when certain options have been available for years. Dr Owens further explains there is no single formula to determine a return on investment for newer agents.
Because the drugs to treat MS are extremely expensive and difficult for patients to afford, Dr Owens and Leslie Fish, PharmD, suggest that when reviewing and negotiating the price of a therapy option, there is a need for transparency and comparative effectiveness.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
2
COPD Deaths Rival Heart Failure, Exceed Prostate and Breast Cancer
3
FDA Approves Camizestrant for ER+, HER2– mBC With ESR1 Mutations
4
COPERNICOS Trial: Eosinophil-Guided ICS Reduction Safe in COPD, Vestbo Says
5





















